Structure Therapeutics (GPCR) Financials

Structure Therapeutics (NASDAQ: GPCR) remains a development-stage biotech with no product revenue, and its financial statements continue to show heavy operating losses alongside a very large cash and investment position. The company’s latest quarter highlights a strong liquidity profile, but also a steep quarterly cash burn and rising share count tied to financing activities.

• Strong balance sheet: As of Q1 2026, GPCR reported $1.46 billion in cash, cash equivalents, and short-term investments, versus $61.0 million in total liabilities. That gives the company substantial funding runway for ongoing clinical development.
• Equity base remains very large: Total common equity was $1.45 billion in Q1 2026, reflecting a balance sheet still dominated by cash and marketable securities rather than debt.
• Operating cash flow was positive in Q1 2026: The company generated $15.2 million of net cash from operations in the quarter, helped by favorable changes in working capital and non-cash adjustments.
• Investments continue to support liquidity: GPCR’s investment portfolio remains sizable, and the company realized cash from investment maturities/sales while still holding a large securities balance.
• No revenue yet: The income statement shows $0 revenue in every quarter provided, so the company is still entirely dependent on financing and its cash reserves.
• Losses remain substantial: Q1 2026 net loss attributable to common shareholders was $79.2 million, with basic and diluted EPS of $(0.35).
• R&D remains the largest expense: Q1 2026 research and development expense was $66.5 million, underscoring continued pipeline investment and clinical-stage spending.
• Interest expense is meaningful: GPCR reported $13.6 million of interest expense in Q1 2026, which adds pressure to pre-tax results despite having a strong cash position.
• Share count has risen over time: Weighted average basic shares increased to 217.3 million in Q1 2026 from 139.7 million in Q1 2024, indicating meaningful dilution.
• Cash burn accelerated in Q1 2026: The company reported a $483.5 million net decrease in cash and equivalents for the quarter, driven largely by heavy investing activity.
• Investing outflows were very large: Q1 2026 net cash used in investing activities totaled $(496.9) million, far exceeding operating inflows and weighing on quarter-end liquidity trends.
• Operating losses are still wide: Operating expenses totaled $89.4 million in Q1 2026, with an operating loss of $89.4 million due to the lack of revenue.
• Cash balance fell sharply from late 2025: Cash and equivalents dropped from $102.9 million in Q3 2025 to $31.6 million in Q1 2026, even though the company still has plenty of short-term investments.

Trend summary: Over the last four years, GPCR has consistently posted losses and zero revenue, but it has also repeatedly raised capital and built a large investment portfolio. That strategy has left it well-capitalized for now, though dilution and ongoing cash usage are important issues for investors to watch. The key question remains whether clinical progress can eventually justify the company’s high spending and balance-sheet resources.